SkyCell – Safe. Secure. Sustainable.
This is more than a strapline for us. It’s our promise to clients, patients and the environment. It’s our contribution to healthcare. Worldwide.
Sustainability needs to be more than a buzzword
SkyCell’s origin is based on sustainability, as the founders developed an insulation technology from 99% recycled material. The analysis of industrial applications revealed that the highest added value is generated by air freight containers for the transport of temperature-sensitive pharmaceuticals.
We believe sustainability is only scalable if it increases efficiency and never compromises on quality. Increasing sustainability must be a win-win for all stakeholders.
The supply chain is a huge part of how a business can tackle emissions and other sustainability issues, and therefore offers tremendous potential for reducing a company’s carbon footprint. Pharma companies such as Takeda or Novo Nordisk lead by example and aim to become carbon neutral by 2040. AstraZeneca goes even one step further and commits to become carbon negative by 2030, according to the announcement made by their CEO Pascal Soriot at this year’s World Economic Forum in Davos.
With every shipment we help our customers to get a little bit closer to their goal. SkyCell has been independently certified by MyClimate as reducing CO2 emissions by almost half compared to commonly used solutions. We have accomplished this by using recycled material to build its containers on one hand and on the other hand by only choosing light materials in order to minimize weight. It is of highest importance to us to not waste any resources that can be reused which is why all our containers are recycled.
Another way of creating a more sustainable supply chain is technology. It acts as an enabler for sustainability – especially as product loss and waste reduction can also be achieved through better supply chain monitoring. This is what we at SkyCell aim to do. The hybrid containers when tested against industry standards not only reduce the total cost by up to 20 percent but also reduce CO2 emissions by up to 50 percent. These reductions have a huge impact on the environmental impact of pharma companies and lead to operational cost savings as a result of less waste and reduced fuel, energy, and transport costs.
*Audit of 15ooDF/F in progress